Overview

Properties

  • Form
    Liquid
  • Storage instructions
    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
  • Storage buffer
    pH: 7.30
    Preservative: 0.02% Sodium azide
    Constituents: Tris buffered saline, 0.5% BSA
  • Concentration information loading...
  • Purity
    Immunogen affinity purified
  • Purification notes
    Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunising peptide.
  • Clonality
    Polyclonal
  • Isotype
    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab15723 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 - 3 µg/ml. Can be blocked with Human Munc 13-4 peptide (ab23273). Approx. 105kDa band observed in Human T-lymphocyte and HeLa lysates (calculated MW of 123kDa according to NP_954712.1)

Target

  • Function
    Plays a role in cytotoxic granule exocytosis in lymphocytes. Required for both granule maturation and granule docking and priming at the immunologic synapse. Regulates assembly of recycling and late endosomal structures, leading to the formation of an endosomal exocytic compartment that fuses with perforin-containing granules at the immunologic synapse and licences them for exocytosis. Regulates Ca(2+)-dependent secretory lysosome exocytosis in mast cells.
  • Tissue specificity
    Expressed at high levels in spleen, thymus and leukocytes. Also expressed in lung and placenta, and at very low levels in brain, heart, skeletal muscle and kidney. Expressed in cytotoxic T-lymphocytes (CTL) and mast cells.
  • Involvement in disease
    Defects in UNC13D are the cause of hemophagocytic lymphohistiocytosis familial type 3 (FHL3) [MIM:608898]; also known as HPLH3. Familial hemophagocytic lymphohistiocytosis (FHL) is a genetically heterogeneous, rare autosomal recessive disorder. It is characterized by immune dysregulation with hypercytokinemia and defective natural killer cell function. The clinical features of the disease include fever, hepatosplenomegaly, cytopenia, hypertriglyceridemia, hypofibrinogenemia, and neurological abnormalities ranging from irritability and hypotonia to seizures, cranial nerve deficits, and ataxia. Hemophagocytosis is a prominent feature of the disease, and a non-malignant infiltration of macrophages and activated T lymphocytes in lymph nodes, spleen, and other organs is also found.
  • Sequence similarities
    Belongs to the unc-13 family.
    Contains 2 C2 domains.
    Contains 1 MHD1 (MUNC13 homology domain 1) domain.
    Contains 1 MHD2 (MUNC13 homology domain 2) domain.
  • Domain
    The MHD1 and MHD2 domains mediate localization on recycling endosomes and lysosome.
  • Cellular localization
    Cytoplasm. Membrane. Late endosome. Recycling endosome. Lysosome. Colocalizes with cytotoxic granules at the plasma membrane. Localizes to endosomal exocytic vesicles.
  • Information by UniProt
  • Database links
  • Form
    There are 3 isoforms produced by alternative splicing.
  • Alternative names
    • FHL 3 antibody
    • FHL3 antibody
    • FLJ00067 antibody
    • HLH 3 antibody
    • HLH3 antibody
    • HPLH 3 antibody
    • HPLH3 antibody
    • Jinx antibody
    • Munc13 4 antibody
    • Munc13-4 antibody
    • Protein unc 13 homolog D antibody
    • Protein unc-13 homolog D antibody
    • UN13D_HUMAN antibody
    • Unc 13 homolog D antibody
    • UNC 13D antibody
    • Unc-13 homolog D (C. elegans) antibody
    • Unc13 homolog D (C elegans) antibody
    • Unc13 homolog D antibody
    • UNC13, C. elegans, homolog of, D antibody
    • UNC13D antibody
    • Unc13h4 antibody
    see all

Images

  • Anti-Munc 13-4 antibody (ab15723) at 2 µg/ml + Cell lysates prepared from human T lymphocytes at 35 µg

    Developed using the ECL technique.

References

ab15723 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

1-5 of 5 Abreviews or Q&A

Answer

Thank you for your enquiry. Unfortunately, in my opinion, this antibody would probably not cross-react mouse. I did an alignment of the immunogen with the mouse sequence, and got only 58% homology. The results are below: KQASQHALRPAP Immunogen RQRAKQASQHAP Mouse sequence :* :::* : ** This is our only Munc13-4 antibody, so I am unable to make a suggestion as to a different antibody that would be appropriate. You may wish to check the World's Antibody Gateway link on our search results page to search through 249 other companies to see if you can find an antibody that would work for you. I'm glad you got to meet our staff at the ASCB. Best of luck in your research! I hope this information helps, please do not hesitate to contact us if you need any more advice or information.

Read More

Answer

Thanks for your email. I'm afraid that I can't tell you who has purchased this antibody, that information is confidential. We have not yet received any feedback about this antibody; when we do receive such feedback we will post that information on the online datasheet. If you have any additional questions, please contact us again.

Read More

Answer

Thanks for your email. The H460 and Human Placenta lysates were the only lysates that have been tested. Please let me know if you have any additional questions.

Read More

Answer

Thank you for your enquiry. As stated on the datasheet, ab15723 is a Fast-Track antibody. Fast-Track antibodies are immunogen affinity purified and are shown by ELISA to have high titre values against their immunogen. We are currently testing them for use in Western blotting. At this stage, there can be delays. We sometimes experience problems in searching for / developing the correct lysate or knock-out cell-line. In addition, certain products can be difficult to characterise, due, for instance, to low expression levels or a lack of expression in easily available lysates. We realise that these products might be very suitable for your research and do not wish to delay this; therefore, we release them early with the following understanding: As Fast-Track antibodies are not yet fully characterised we are unable to offer our normal level of technical support. We cannot guarantee that the antibody will work in any application other than ELISA against the immunizing peptide and therefore we are unable to offer a refund if the antibody does not work in your application. The preliminary testing that has been done with ab15723 is the following: ab15723 was used as concentrations up to 1 ug/ml on H460 and Human Placenta lysates. No specific signal was seen but there was low background. You should know that we would greatly appreciate your feedback on these antibodies, whether positive or negative. We will award $300 of Conference Travel Money to the first researcher who sends us positive feedback (including an image and details of materials & methods). Conclusive negative feedback that leads us to withdraw the antibody will also be rewarded with $300 of Conference Travel Money. If you have any additional questions, please contact us again.

Read More

Answer

Thank you for your enquiry regarding ab15723. As stated on the datasheet, ab15723 is a Fast-Track antibody. Fast-Track antibodies are immunogen affinity purified and are shown by ELISA to have high titre values against their immunogen. We are currently testing them for use in Western blotting. At this stage, there can be delays. We sometimes experience problems in searching for / developing the correct lysate or knock-out cell-line. In addition, certain products can be difficult to characterise, due, for instance, to low expression levels or a lack of expression in easily available lysates. We realise that these products might be very suitable for your research and do not wish to delay this; therefore, we release them early with the following understanding: As Fast-Track antibodies are not yet fully characterised we are unable to offer our normal level of technical support. We cannot guarantee that the antibody will work in any application other than ELISA against the immunizing peptide and therefore we are unable to offer a refund if the antibody does not work in your application. Ab15723 has not been tested yet in FACS; there is only some preliminary results at this point for Western blotting. I'm afraid that I can only suggest at this point to increase the amount of primary antibody that you are using, and increase the incubation period. You should know that we would greatly appreciate your feedback on these antibodies, whether positive or negative. We will award $300 of Conference Travel Money to the first researcher who sends us positive feedback (including an image and details of materials & methods). Conclusive negative feedback that leads us to withdraw the antibody will also be rewarded with $300 of Conference Travel Money. If you have any additional questions, please contact us again.

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up